Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rosuvastatin + ezetimibe + bempedoic acid
- Development stage
- Preclinical
- Lead developer
- Althera Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
rosuvastatin + ezetimibe + bempedoic acid is an oral fixed-dose small-molecule combination being developed by Althera Pharma for hyperlipidemia and cardiovascular risk reduction. The regimen combines three complementary LDL-cholesterol lowering mechanisms: rosuvastatin inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase to reduce hepatic cholesterol synthesis and increase LDL receptor expression, ezetimibe inhibits intestinal cholesterol absorption through Niemann-Pick C1-Like 1, and bempedoic acid inhibits adenosine triphosphate citrate lyase upstream of HMG-CoA reductase to further suppress cholesterol biosynthesis. Based on the provided Althera Pharma pipeline context, this product is positioned as a dossier-ready branded combination in late-stage regulatory preparation rather than a novel discovery asset, with listed strengths including 180/10/40 mg, 180/10/20 mg, and 180/10/10 mg.
- Other names
- rosuvastatin + ezetimibe + bempedoic acidrosuvastatin/ezetimibe/bempedoic acid
02
Targets
ACLY (ATP-citrate synthase)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on rosuvastatin + ezetimibe + bempedoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rosuvastatin + ezetimibe + bempedoic acid.